|Bid||115.00 x 800|
|Ask||118.14 x 800|
|Day's Range||117.51 - 119.98|
|52 Week Range||62.88 - 131.95|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||174.79|
|Earnings Date||Oct 21, 2020 - Oct 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||134.82|
The EMA sanctions BioMarin's (BMRN) marketing authorization application for vosoritide to treat children with achondroplasia, the most common type of dwarfism.
Ascendis' (ASND) TransCon CNP receives an Orphan Drug tag in Europe for the treatment of achondroplasia, the most common type of dwarfism.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of disproportionate short stature in humans. The MAA review will commence on August 13, 2020.